​

Protagenic Therapeutics Stock (NASDAQ:PTIX)

RevenueOwnershipFinancialsChart

Previous Close

$3.39

52W Range

$2.35 - $15.54

50D Avg

$3.81

200D Avg

$6.20

Market Cap

$3.06M

Avg Vol (3M)

$2.05M

Beta

0.38

Div Yield

-

PTIX Company Profile

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1

IPO Date

Apr 27, 2021

Website

PTIX Performance

PTIX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-5.70M$-4.53M$-3.56M
Net Income$-5.53M$-5.00M$-3.60M
EBITDA$-5.70M$-4.50M$-3.42M
Basic EPS$-1.13$-1.15$-0.83
Diluted EPS$-1.13$-1.15$-0.83

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 23Apr 01, 24 | 4:30 PM

Peer Comparison

TickerCompany
ADAGAdagene Inc.
ELDNEledon Pharmaceuticals, Inc.
RZLTRezolute, Inc.
TPSTTempest Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
AVTEAerovate Therapeutics, Inc.
ANTXAN2 Therapeutics, Inc.